PATENT CLAIM ANALYSIS

Application Number: 15880726
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["424", "142100"]

Abstract:
The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.

Claim (Index 22):
The method according to  claim 21 , wherein the anti-GM-CSF antibody comprises a variable heavy chain peptide of sequence: (SEQ\u2003ID\u2003NO:\u20038) QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMNWVRQAPGKGLEWVSG   IENKYAGGATYYAASVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR   GFGTDFWGQGTLVTVSS and a variable light chain peptide of sequence: (SEQ\u2003ID\u2003NO:\u20039) DIELTQPPSVSVAPGQTARISCSGDSIGKKYAYWYQQKPGQAPVLVIYKK   RPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCSAWGDKGMVFGGGTK   LTVLGQ.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 86.0
- Lexical Diversity: 1.25
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13877585', '15654854', '14904864', '12704396', '12157599']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7047562465684041
- 35 USC 102 Novelty (BERT): 0.510955829317692
- Combined Prediction Score: 0.6853762048433328
- Mean Citation Score: 230.968688
- Max Citation Score: 254.1106
- Similarity Product: 163.73533010759354

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test